EUVIMEDEUVIMED entdecken
Crossref

Intracranial Nanogel Pellets Carrying Temozolomide and Paclitaxel for Adjuvant Brain Cancer Therapy

Hasan Slika, Aanya Shahani, Kranthi Gattu, Varsha Mundrathi, Ameilia A Solan, Brianna Gonzalez, Tasmima N Haque, Sadia Rahman, Vrashabh V Sugandhi, Jennifer Lee, Esteban Velarde, Safwan Alomari und 5 weitere

Molecular Pharmaceutics · 06.01.2025 · 22 (1) · 131-141

DOI: 10.1021/acs.molpharmaceut.4c00708 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 12.12.2024. Verfasst von Hasan Slika und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hunterian Neurosurgical Laboratory, Department of Neurosurgery, School of Medicine, The Johns Hopkins University, Baltimore, Maryland 21231, United S…. Hauptthemen laut MEDLINE: Temozolomide, Paclitaxel, Brain Neoplasms, Nanogels. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 25 Literaturangaben. Gefördert von: OncoGone Inc., Khatib Brain Tumor Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma multiforme is the most frequently diagnosed primary malignant brain tumor. Despite multimodal therapy with surgical resection, radiation therapy, and chemotherapy, recurrence of the tumor is almost always guaranteed due to the infiltrative nature of the disease. Moreover, the blood brain barrier imparts an additional layer of complexity by impeding the delivery of therapeutic agents to the tumor, hence limiting the efficacy of systemically delivered drugs. Hence, to overcome this obstacle and avoid treatment resistance, the local delivery of combination therapies has risen as an appealing adjuvant treatment. The present study describes the creation of a novel PLGA-PEG-PLGA-based nanogel pellet system for the interstitial delivery of Temozolomide (TMZ) and paclitaxel (PTX) to the brain. The nanogel pellet was shown to be stable as a pellet at ambient temperature, absorb water, change to a gel formulation at physiological temperature, and achieve gradual long-term release of TMZ and PTX in vitro. Additionally, in vivo testing of the TMZ/PTX-loaded nanogel pellets in an orthotopic CT2A mouse model and an orthotopic 9L rat model has shown an acceptable safety profile when implanted intracranially and a significant improvement in overall survival.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TemozolomidePaclitaxelBrain NeoplasmsNanogelsPolyethylene GlycolsAnimalsGlioblastomaRatsMiceCell Line, TumorHumansPolyethyleneimineMaleDrug Delivery SystemsDrug CarriersBlood-Brain Barrier

Stichwörter der Autor:innen

animal modelcombination therapydrug deliveryglioblastoma multiformegliomananogelthermosensitive gel

Substanzen

TemozolomidePaclitaxelNanogelsPolyethylene GlycolsPolyethyleneimineDrug Carrierspolyethylene glycol polyethyleneimine nanogel

Autor:innen und Institutionen

  • Hunterian Neurosurgical Laboratory, Department of Neurosurgery, School of Medicine, The Johns Hopkins University, Baltimore, Maryland 21231, United States.
  • Industrial Pharmacy, Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York 11439, United States.
  • Department of Radiation Oncology and Molecular Sciences, School of Medicine, The Johns Hopkins University, Baltimore, Maryland 21231, United States.
  • Department of Ophthalmology, School of Medicine, The Johns Hopkins University, Baltimore, Maryland 21231, United States.
  • Department of Biomedical Engineering, School of Medicine, The Johns Hopkins University, Baltimore, Maryland 21231, United States.
  • Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, School of Medicine, The Johns Hopkins University, Baltimore, Maryland 21231, United States.

ORCID-Profile: Hyunah Cho

Förderung

  • OncoGone Inc.
  • Khatib Brain Tumor Center

Zitieren

APA

Slika, H., Shahani, A., Gattu, K., Mundrathi, V., Solan, A. A., Gonzalez, B., Haque, T. N., Rahman, S., Sugandhi, V. V., Lee, J., Velarde, E., Alomari, S., Pacis, V. L., Brem, H., Tyler, B., Xin, X., & Cho, H. (2025). Intracranial Nanogel Pellets Carrying Temozolomide and Paclitaxel for Adjuvant Brain Cancer Therapy. Molecular Pharmaceutics, 22(1), 131-141. https://doi.org/10.1021/acs.molpharmaceut.4c00708

Vancouver

Slika H, Shahani A, Gattu K, Mundrathi V, Solan AA, Gonzalez B, et al. Intracranial Nanogel Pellets Carrying Temozolomide and Paclitaxel for Adjuvant Brain Cancer Therapy. Molecular Pharmaceutics. 2025;22(1):131-141. doi:10.1021/acs.molpharmaceut.4c00708

BibTeX
@article{Slika2025,
  author = {Slika, Hasan and Shahani, Aanya and Gattu, Kranthi and Mundrathi, Varsha and Solan, Ameilia A and Gonzalez, Brianna and Haque, Tasmima N and Rahman, Sadia and Sugandhi, Vrashabh V and Lee, Jennifer and Velarde, Esteban and Alomari, Safwan and Pacis, Victor Lance and Brem, Henry and Tyler, Betty and Xin, Xiaoban and Cho, Hyunah},
  title = {Intracranial Nanogel Pellets Carrying Temozolomide and Paclitaxel for Adjuvant Brain Cancer Therapy},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  volume = {22},
  number = {1},
  pages = {131--141},
  doi = {10.1021/acs.molpharmaceut.4c00708}
}
Kostenlos starten →